Structure based screening of ligands against dTDP-6-deoxy-D-xylo-4-hexulose 3, 5-epimerase (RmlC): phytochemical as drug candidate for Mycobacterium tuberculosis

Jyoti Prakash Rath, Mukesh Kumar Raval

Abstract


Objective: RmlC (dTDP-6-deoxy-D-xylo-4-hexulose 3, 5-epimerase) is a crucial enzyme for cell wall biosynthesis in Mycobacterium tuberculosis. It’s absence in human host attest it as a valid target for drug designing. In the presented study an in-silico method is employed to find out the potential phytochemical inhibitors of RmlC.

Methods: AutoDock 4.2 is used to study the binding affinity of ligands in the active site of the protein. The drug-likeness and oral toxicity evaluation is done using the online tools Molsoft and ProTox respectively.

Results: Chrysophanol has binding affinity of -9.24 kcal/mole to RmlC active site. PASS tool predicts chrysophanol as antitubercular compound. Its druglikeness is 0.1, and toxicity class is 5 measured by ProTox. Hence, chrysophanol emerges as a lead molecule among the phytochemicals in the database.

Conclusions: Crysophanol is the lead inhibitor against RmlC target. The lead molecule may work as a successful drug in future for tuberculosis treatment.


Keywords


RmlC, Tuberculosis, Crysophanol, Drug-likeness, Toxicity, Molsoft, ProTox

Full Text:

PDF HTML XML

References


World Health Organization, Global tuberculosis report 2016. Available at http://www.who.int/tb/publications/global_report/en/. Accessed on 15 Feb 2017.

Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev. 2006;19(4):658-85.

Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263(5144):227-30

Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science. 1998;280(5369):1607-10.

Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 1998;27:249-84.

Ma Y, Pan F, McNeil M. Formation of dTDP-rhamnose is essential for growth of mycobacteria. J Bacteriol. 2002; 184(12):3392-5.

Gabriel O, Ashwell G. Biological mechanisms involved in the formation of deoxysugars. II. Enzymatic conversion of thymidine diphosphoglucose-3T to thymidine diphospho -4- keto -6-deoxyglucose. J Biol Chem. 1965; 240(11):4128-32.

Graninger M, Nidetzky B, Heinrichs DE, Whitfield C, Messner P. Characterization of dTDP-4-dehydrorhamnose 3,5-epimerase and dTDP-4-dehydrorhamnose reductase, required for dTDP-L-rhamnose biosynthesis in Salmonella enterica serovar Typhimurium LT2. J Biol Chem. 1999;274(35):25069-77.

Melo A, Elliott WH, Glaser L. The mechanism of 6-deoxyhexose synthesis. I. Intramolecular hydrogen transfer catalyzed by deoxythymidine diphosphate D-glucose oxidoreductase. J Biol Chem. 1968; 243(7):1467-74.

Nikaido H, Nikaido K, Rapin AM. Biosynthesis of thymidine diphosphate L-rhamnose in Escherichia coli K-12. Biochim Biophys Acta. 1965;111(2):548-51.

Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670-95.

Ahmad I, Aqil F. In vitro efficacy of bioactive extracts of 15 medicinal plants against ESbetaL-producing multidrug-resistant enteric bacteria. Microbiol Res. 2007;162(3):264-75

Dong C, Major LL, Srikannathasan V, Errey JC, Giraud MF, Lam JS, et al. RmlC, a C3' and C5' carbohydrate epimerase, appears to operate via an intermediate with an unusual twist boat conformation. J Mol Biol. 2007;365(1):146-59.

Dong C, Major LL, Allen A, Blankenfeldt W, Maskell D, Naismith JH. High-resolution structures of RmlC from Streptococcus suis in complex with substrate analogs locate the active site of this class of enzyme. Structure. 2003;11(6):715-23.

Mangal M, Sagar P, Singh H, Raghava GPS, Agarwal SM. NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database. Nucleic Acids Res. 2013;41:D1124-9.

Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11(5):905-19.

O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011;3:33.

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-91.

Borodina Y, Filimonov DA, Poroikov VV. Computer-aided prediction of prodrug activity using the pass system. Pharm Chem J. 1996;30(12):760–3.

Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R. ProTox: A web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res. 2014;42(Web server issue):W53-8.

Schmidt U, Struck S, Gruening B, Hossbach J, Jaeger IS, Parol R, et al. SuperToxic: a comprehensive database of toxic compounds. Nucleic Acids Res. 2009;37:D295-9.

Sivendran S, Jones V, Sun D, Wang Y, Grzegorzewicz AE, Scherman MS, et al. Identification of triazinoindol-benzimida-zolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC). Bioorg Med Chem. 2010;18(2):896-908.




DOI: http://dx.doi.org/10.26510/2394-0859.pbe.2017.15

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2018 - Pharmaceutical and Biological Evaluations